Piper Sandler Maintains Neutral on Fulgent Genetics, Lowers Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Westenberg maintains a Neutral rating on Fulgent Genetics (NASDAQ:FLGT) and lowers the price target from $37 to $28.
October 16, 2023 | 5:25 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Piper Sandler has maintained a Neutral rating on Fulgent Genetics and lowered the price target from $37 to $28.
The lowering of the price target by Piper Sandler from $37 to $28 indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on Fulgent Genetics' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100